Board of Directors

Denis Guttridge

  • Grey LinkedIn Icon

I’m a paragraph. Double click me or click Edit Text, it's easy.

Vickie E Baracos

  • Professor, Alberta Cancer Foundation Chair in Palliative Care Medicine

  • Department of Oncology, University of Alberta, Canada

  • BSc 1977 University of Alberta, Animal Science

  • PhD 1981 Nottingham University, Applied Biochemistry

  • PDF 1981 Harvard Medical School, Physiology

The long term focus of my career has been the pathophysiology of skeletal muscle atrophy in an effort that encompasses fundamental and translational research, a clinical research agenda and an international network of strategic collaboration. Cancer cachexia, a debilitating condition characterized by profound atrophy of skeletal muscle is my main focus since 2003. Some key publications include Baracos VE et al. Cancer-associated cachexia. Nat Rev Dis Primers. 2018; 4:17105; Martin L et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33(1):90-9. Fearon K et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-95. I developed the use of clinical computed tomography to detect and precisely measure the muscle loss which is an integral part of cachexia.  Muscle loss is strongly associated with severe chemotherapy toxicity, complications of surgery and mortality in patients with different cancers.

Jose Garcia

Aminah Jatoi

  • Grey LinkedIn Icon

I’m a paragraph. Double click me or click Edit Text, it's easy.

Andrew Judge

  • Grey LinkedIn Icon

I’m a paragraph. Double click me or click Edit Text, it's easy.

Richard Skipworth

The long term focus of my career has been the pathophysiology of skeletal muscle atrophy in an effort that encompasses fundamental and translational research, a clinical research agenda and an international network of strategic collaboration. Cancer cachexia, a debilitating condition characterized by profound atrophy of skeletal muscle is my main focus since 2003. Some key publications include Baracos VE et al. Cancer-associated cachexia. Nat Rev Dis Primers. 2018; 4:17105; Martin L et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33(1):90-9. Fearon K et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-95. I developed the use of clinical computed tomography to detect and precisely measure the muscle loss which is an integral part of cachexia.  Muscle loss is strongly associated with severe chemotherapy toxicity, complications of surgery and mortality in patients with different cancers.

Aminah Jatoi

  • Grey LinkedIn Icon

I’m a paragraph. Double click me or click Edit Text, it's easy.

Andrew Judge

  • Grey LinkedIn Icon

I’m a paragraph. Double click me or click Edit Text, it's easy.

Richard Skipworth

The long term focus of my career has been the pathophysiology of skeletal muscle atrophy in an effort that encompasses fundamental and translational research, a clinical research agenda and an international network of strategic collaboration. Cancer cachexia, a debilitating condition characterized by profound atrophy of skeletal muscle is my main focus since 2003. Some key publications include Baracos VE et al. Cancer-associated cachexia. Nat Rev Dis Primers. 2018; 4:17105; Martin L et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33(1):90-9. Fearon K et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-95. I developed the use of clinical computed tomography to detect and precisely measure the muscle loss which is an integral part of cachexia.  Muscle loss is strongly associated with severe chemotherapy toxicity, complications of surgery and mortality in patients with different cancers.

© 2019-2020 – Cancer Cachexia Society | All rights reserved.